155 related articles for article (PubMed ID: 28623682)
1. Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report.
Keribin P; Guerrot D; Jardin F; Moizan H
J Oral Maxillofac Surg; 2017 Dec; 75(12):2599-2605. PubMed ID: 28623682
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
Yarom N; Yahalom R; Shoshani Y; Hamed W; Regev E; Elad S
Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
Fusco V; Santini D; Armento G; Tonini G; Campisi G
Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
[TBL] [Abstract][Full Text] [Related]
7. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Antonuzzo L; Lunghi A; Petreni P; Brugia M; Laffi A; Giommoni E; Mela MM; Mazzoni F; Balestri V; Costanzo FD
Curr Med Chem; 2017; 24(28):3068-3076. PubMed ID: 28494743
[TBL] [Abstract][Full Text] [Related]
9. Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder.
Sullivan BJ; Kim GJ; Sara G
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567238
[TBL] [Abstract][Full Text] [Related]
10. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
11. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
12. [Bisphosphonate-associated osteonecrosis of the jaw].
Krauth MT; Fügl A; Gruber R
Wien Klin Wochenschr; 2008; 120(15-16):467-76. PubMed ID: 18820850
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.
Iu LP; Yeung JC; Loong F; Chiang AK
Pediatr Blood Cancer; 2015 Jan; 62(1):169-72. PubMed ID: 25174958
[TBL] [Abstract][Full Text] [Related]
14. Usefulness and limitations of rituximab in managing patients with lymphoproliferative disorder after heart transplantation.
Senechal M; Demers S; Cantin B; Bourgault C; Leblanc MH; Morin J; Couture C
Exp Clin Transplant; 2012 Oct; 10(5):513-8. PubMed ID: 22747415
[TBL] [Abstract][Full Text] [Related]
15. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor.
Nieto-Rios JF; Gómez de Los Ríos SM; Serna-Higuita LM; Ocampo-Kohn C; Aristizabal-Alzate A; Gálvez-Cárdenas KM; Zuluaga-Valencia GA
Colomb Med (Cali); 2016 Dec; 47(4):196-202. PubMed ID: 28293043
[TBL] [Abstract][Full Text] [Related]
16. Combined Lung-Liver and Delayed Kidney Transplantation for Cystic Fibrosis Clinical Approach and Outcome: A Case Report.
Zhang T; Price MB; Bravo N; Villarreal JA; Kueht ML; Vierling JM; Cotton R; Galvan T; O'Mahony CA; Goss JA; Rana A
Transplant Proc; 2020 Nov; 52(9):2824-2826. PubMed ID: 32389488
[TBL] [Abstract][Full Text] [Related]
17. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
Bagán J; Blade J; Cozar JM; Constela M; García Sanz R; Gómez Veiga F; Lahuerta JJ; Lluch A; Massuti B; Morote J; San Miguel JF; Solsona E
Med Oral Patol Oral Cir Bucal; 2007 Aug; 12(4):E336-40. PubMed ID: 17664922
[No Abstract] [Full Text] [Related]
19. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder.
Francescone SA; Murphy B; Fallon JT; Hammond K; Pinney S
Transplant Proc; 2009 Jun; 41(5):1946-8. PubMed ID: 19545762
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
